慢性炎症性脱髓鞘性多发性神经病
医学
相伴的
耐火材料(行星科学)
多发性神经病
霉酚酸酯
内科学
药物治疗
皮质类固醇
胃肠病学
抗体
免疫学
移植
天体生物学
物理
作者
Gurdesh S Bedi,Andrew Brown,Tao Tong,Khema R. Sharma
标识
DOI:10.1136/jnnp.2009.177576
摘要
Objective
To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). Background
Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. Methods
A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. Results
Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3±35) after initiation of MMF therapy (37.8±37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by ≥50%. Conclusions
Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.
科研通智能强力驱动
Strongly Powered by AbleSci AI